3E0 Stock Chart & Stats
€61.22
-€1.26(-1.55%)
At close: 4:00 PM EDT
€61.22
-€1.26(-1.55%)
Day’s Range― - ―
52-Week Range€33.20 - €83.28
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€1.68B
Enterprise Value€2.78K
Total Cash (Recent Filing)€71.16M
Total Debt (Recent Filing)€263.67M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 10, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding29,801,891
10 Day Avg. Volume3
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)91.68
Price to Sales (P/S)10.23
P/FCF Ratio-37.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€90.09Price Target Upside47.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.03
Revenue Forecast (FY)€232.28M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross MarginRevenue growth alongside a strong gross margin indicates meaningful product demand and attractive unit economics in the core implant business. If maintained, this combination can provide the gross-profit base needed to fund commercial expansion and support eventual operating leverage.
Narrowing LossesThe substantial reduction in net losses shows progress toward a more sustainable earnings profile, even though profitability has not yet been reached. Continued improvement would reduce the funding burden, strengthen financial resilience, and increase the likelihood of reaching break-even.
Low Current LeverageVery low reported debt materially limits interest and refinancing pressure compared with the company’s earlier leverage levels. This gives management greater flexibility to direct resources toward growth and operational improvement while the business works to restore profitability.
Bears Say
Ongoing UnprofitabilityThe company remains structurally unprofitable despite improving losses and strong gross margins. Negative operating and net margins constrain internally generated funding, make earnings more sensitive to execution, and leave profitability restoration as a central requirement for durable financial strength.
Negative Cash GenerationPersistent negative operating and free cash flow means the business is not yet funding its operations and investment needs from internally generated cash. Although cash burn has improved, continued deficits can require external funding or balance-sheet flexibility until sustained break-even is achieved.
Thin Equity BaseA relatively small equity base compared with total assets provides less capital cushion while losses continue, and deeply negative returns on equity show that capital is not yet producing attractive results. Strengthening equity through sustained profitability remains important for long-term resilience.
Establishment Labs Holdings News
3E0 FAQ
What was Establishment Labs Holdings Inc’s price range in the past 12 months?
Establishment Labs Holdings Inc lowest stock price was €33.20 and its highest was €83.28 in the past 12 months.
What is Establishment Labs Holdings Inc’s market cap?
Establishment Labs Holdings Inc’s market cap is €1.68B.
When is Establishment Labs Holdings Inc’s upcoming earnings report date?
Establishment Labs Holdings Inc’s upcoming earnings report date is Nov 10, 2026 which is in 39 days.
How were Establishment Labs Holdings Inc’s earnings last quarter?
Establishment Labs Holdings Inc released its earnings results on Aug 06, 2026. The company reported -€0.344 earnings per share for the quarter, missing the consensus estimate of -€0.297 by -€0.047.
Is Establishment Labs Holdings Inc overvalued?
According to Wall Street analysts Establishment Labs Holdings Inc’s price is currently Undervalued.
Does Establishment Labs Holdings Inc pay dividends?
Establishment Labs Holdings Inc does not currently pay dividends.
What is Establishment Labs Holdings Inc’s EPS estimate?
Establishment Labs Holdings Inc’s EPS estimate is -0.23.
How many shares outstanding does Establishment Labs Holdings Inc have?
Establishment Labs Holdings Inc has 29,801,891 shares outstanding.
What happened to Establishment Labs Holdings Inc’s price movement after its last earnings report?
Establishment Labs Holdings Inc reported an EPS of -€0.344 in its last earnings report, missing expectations of -€0.297. Following the earnings report the stock price went down -2.896%.
Which hedge fund is a major shareholder of Establishment Labs Holdings Inc?
Currently, no hedge funds are holding shares in DE:3E0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Establishment Labs Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€90.09 (47.17% Upside)
€90.09 (47.17% Upside)
Blogger Sentiment
Bullish
DE:3E0 Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
3E0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and commercial momentum led by a rapid U.S. launch, 45% YoY revenue growth in Q1, improving gross margin (70.7%) and a return to positive adjusted EBITDA. Key product innovations (minimally invasive platform) are driving adoption, surgeon and patient demand, and management raised full-year revenue guidance. Offsetting factors include elevated operating expenses, near-term cash usage and increased debt with PIK mechanics, plus some supply and geopolitical uncertainties. Overall, the positives around revenue acceleration, margin expansion, product differentiation and pathway to cash-flow positivity materially outweigh the risks discussed.View all DE:3E0 earnings summaries3E0 Stock 12 Month Forecast
Average Price Target
€90.09
▲(47.17% Upside)